BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23793142)

  • 1. Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: a prospective, observational study.
    Gascón P; Rodríguez CA; Valentín V; Mata JG; Carulla J; Cassinello J; Colomer R; Baró E
    Support Care Cancer; 2013 Nov; 21(11):3039-49. PubMed ID: 23793142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychometric properties of the Perform Questionnaire: a brief scale for assessing patient perceptions of fatigue in cancer.
    Baró E; Carulla J; Cassinello J; Colomer R; Mata JG; Gascón P; Gasquet JA; Rodríguez CA; Valentín V
    Support Care Cancer; 2011 May; 19(5):657-66. PubMed ID: 20432046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
    Hudis CA; Vogel CL; Gralow JR; Williams D;
    Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
    Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
    Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
    Mel JR; Salar A; Rodríguez CA; Alegre A; González A; Cassinello J; Montesinos J; Gasquet JA; Sánchez J; Saigí E;
    Curr Med Res Opin; 2008 Oct; 24(10):2931-42. PubMed ID: 18775103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
    Gabrilove JL; Cleeland CS; Livingston RB; Sarokhan B; Winer E; Einhorn LH
    J Clin Oncol; 2001 Jun; 19(11):2875-82. PubMed ID: 11387360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective cohort study on the impact of darbepoetin alfa on quality of life in daily practice following anemia treatment guideline revisions.
    Steinmetz T; Kindler M; Lange O; Vehling-Kaiser U; Kuhn A; Hellebrand E
    Curr Med Res Opin; 2014 Sep; 30(9):1813-20. PubMed ID: 24849527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
    Canon JL; Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Legg J; Pujol B; Bridges K
    Med Oncol; 2012 Sep; 29(3):2291-9. PubMed ID: 22081263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An induction dose of epoetin alpha of 40 000 IU daily for three consecutive days increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Mustacchi G; Ceccherini R; Dellach C; Foladore S; Milani S; Leita M; Sisto M
    Ann Oncol; 2006 Nov; 17(11):1705-8. PubMed ID: 16980603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Darbepoetin alpha as treatment for anemia in patients receiving chemotherapy: a single-center experience.
    Bartsch R; Wenzel C; Sevelda U; Hussian D; Pluschnig U; Locker GJ; Mader R; Zielinski CC; Steger GG
    Anticancer Drugs; 2005 Jul; 16(6):617-20. PubMed ID: 15930888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level.
    Esquerdo G; Llorca C; Cervera JM; Orts D; Juárez A; Carrato A
    Clin Transl Oncol; 2011 May; 13(5):341-7. PubMed ID: 21596663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-weekly dose of epoetinum alfa in cancer patients with anemia receiving radiotherapy.
    Ots PM; Pérez AR; Carrizosa CL; Ocaña CV; de Dios Sáez Garrido J; Delgado Pérez JM
    Clin Transl Oncol; 2005 Dec; 7(11):486-92. PubMed ID: 16373059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O; Garassino M; Sacchetta S; Caristo R; Zivi A; Cerbone L; Mancuso A
    Anticancer Res; 2008; 28(3B):1767-71. PubMed ID: 18630457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.
    Cortesi E; Gascón P; Henry D; Littlewood T; Milroy R; Pronzato P; Reinhardt U; Shasha D; Thatcher N; Wilkinson P
    Oncology; 2005; 68 Suppl 1():22-32. PubMed ID: 15855813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy.
    Cella D; Viswanathan HN; Hays RD; Mendoza TR; Stein KD; Pasta DJ; Foreman AJ; Vadhan-Raj S; Kallich JD
    Cancer; 2008 Sep; 113(6):1480-8. PubMed ID: 18642348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
    Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
    Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
    Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.